Arecor Therapeutics plc announced that it has signed a further collaboration agreement with Eli Lilly and Company. Under the terms of this agreement, Arecor will use its proprietary formulation technology platform, Arestattm, to develop a novel liquid formulation of one of Lilly's products with enhanced properties. Lilly will fund the development work and has the option to acquire the rights to the new formulation and newly created intellectual property under a technology licensing model to further develop and commercialise the product.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
131 GBX | 0.00% | -4.03% | -28.22% |
May. 16 | EARNINGS AND TRADING: Michelmersh continues with positive order intake | AN |
May. 16 | Transcript : Arecor Therapeutics plc, 2023 Earnings Call, May 16, 2024 |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-28.22% | 50.84M | |
+33.63% | 50.85B | |
-0.09% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+11.18% | 26.11B | |
-21.95% | 19.13B | |
+8.61% | 13.05B | |
+28.31% | 12.16B | |
+24.73% | 12.08B |
- Stock Market
- Equities
- AREC Stock
- News Arecor Therapeutics plc
- Arecor Therapeutics plc Signs Further Collaboration Agreement with Lilly and Company